Maia Wealth LLC Sells 95 Shares of Johnson & Johnson (NYSE:JNJ)

Maia Wealth LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% during the third quarter, Holdings Channel reports. The fund owned 3,473 shares of the company’s stock after selling 95 shares during the period. Maia Wealth LLC’s holdings in Johnson & Johnson were worth $568,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Umpqua Bank grew its position in Johnson & Johnson by 2.3% during the 3rd quarter. Umpqua Bank now owns 18,867 shares of the company’s stock worth $3,058,000 after acquiring an additional 423 shares during the last quarter. Benchmark Financial Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 5.3% during the 3rd quarter. Benchmark Financial Wealth Advisors LLC now owns 1,520 shares of the company’s stock worth $246,000 after buying an additional 76 shares in the last quarter. Radnor Capital Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth $9,318,000. Wisconsin Capital Management LLC acquired a new position in Johnson & Johnson during the 3rd quarter worth $203,000. Finally, Catalina Capital Group LLC lifted its holdings in Johnson & Johnson by 22.2% during the 3rd quarter. Catalina Capital Group LLC now owns 8,098 shares of the company’s stock worth $1,312,000 after buying an additional 1,473 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of several research reports. Wells Fargo & Company upped their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Sanford C. Bernstein increased their price target on Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Finally, Citigroup increased their price target on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Price Performance

JNJ stock opened at $157.76 on Thursday. The stock has a 50-day moving average price of $162.96 and a two-hundred day moving average price of $155.76. The stock has a market cap of $379.83 billion, a PE ratio of 22.83, a price-to-earnings-growth ratio of 2.81 and a beta of 0.53. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.66 EPS. Equities analysts forecast that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.14%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.